Expression of MRP1, BCRP, LRP, and ERCC1 in Advanced Non–Small-Cell Lung Cancer: Correlation With Response to Chemotherapy and Survival
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference37 articles.
1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials;Non-Small Cell Lung Cancer Co-operative Group;BMJ,1995
2. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life;Cellen;J Clin Oncol,1999
3. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer;Schiller;N Engl J Med,2002
4. Randomized phase II study of cisplatin plus irrinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan;Ohe;Ann Oncol,2007
5. A family of drug transporters: the multidrug-resistance-associated proteins;Borst;J Natl Cancer Inst,2000
Cited by 58 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A cisplatin and disulphiram co-loaded inclusion complex overcomes drug resistance by inhibiting cancer cell stemness in non-small cell lung cancer;Journal of Drug Targeting;2024-01-07
2. A macrocyclic peptide inhibitor traps MRP1 in a catalytically incompetent conformation;Proceedings of the National Academy of Sciences;2023-03-09
3. Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum‐based doublet chemotherapy;Journal of Biochemical and Molecular Toxicology;2022-12-11
4. Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel;International Journal of Molecular Sciences;2022-12-04
5. Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)2, in Reversing Multidrug Resistance Mediated by Breast Cancer Resistance Protein (BCRP/ABCG2);International Journal of Molecular Sciences;2022-10-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3